ストックスクリーナーアプリを入手
3.15
3.28%
0.10
アフターアワーズ：
3.15
前日終値:
$3.05
開ける：
$3.08
24時間の取引高:
170.28K
Relative Volume:
0.41
時価総額：
$121.53M
収益：
-
当期純損益:
$-42.05M
株価収益率:
-1.117
EPS:
-2.82
ネットキャッシュフロー:
$-35.26M
1週間 パフォーマンス:
-2.17%
1か月 パフォーマンス:
-0.63%
6か月 パフォーマンス:
-31.97%
1年 パフォーマンス:
+31.25%
1日の値動き範囲:
$3.06
$3.18
1週間の範囲:
$3.022
$3.225
52週間の値動き範囲:
$1.595
$10.48
Protara Therapeutics Inc Stock (TARA) Company Profile
名前
Protara Therapeutics Inc
セクター
電話
646-844-0337
住所
345 PARK AVENUE SOUTH, NEW YORK, NY
TARA を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
TARA
Protara Therapeutics Inc
|
3.15 | 124.23M | 0 | -42.05M | -35.26M | -2.82 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.55 | 123.00B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.93 | 59.66B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
322.81 | 41.84B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
577.92 | 33.98B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
279.16 | 27.67B | 3.81B | -644.79M | -669.77M | -6.24 |
Protara Therapeutics Inc Stock (TARA) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-04-16 | 開始されました | Scotiabank | Sector Outperform |
| 2025-03-14 | 開始されました | Cantor Fitzgerald | Overweight |
| 2023-07-10 | 再開されました | Guggenheim | Buy |
| 2021-06-04 | 開始されました | H.C. Wainwright | Buy |
| 2021-02-17 | 開始されました | Oppenheimer | Outperform |
| 2020-10-19 | 開始されました | Cowen | Outperform |
| 2020-07-29 | 開始されました | Guggenheim | Buy |
すべてを表示
Protara Therapeutics Inc (TARA) 最新ニュース
What makes Protara Therapeutics Inc. stock price move sharplyMinimized Risk Trading Plan - Newser
Why Protara Therapeutics Inc. stock attracts strong analyst attentionValue Pick Scanner - Newser
How Protara Therapeutics Inc. stock performs during market volatilityStable Stocks With High Yield - Newser
Protara Therapeutics Awards 44,250 Equity Grants Worth $2.80 Per Share to Strategic New Hires - Stock Titan
TARA SEC FilingsProtara Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Protara Therapeutics, Inc.(NasdaqGM: TARA) added to Russell 3000E Index - MarketScreener
Protara Therapeutics, Inc. Added to Russell 3000® Index, Enhancing Visibility in Financial Community - Nasdaq
Protara Therapeutics, Inc. (NASDAQ:TARA) Given Average Rating of “Buy” by Brokerages - Defense World
Protara Therapeutics (TARA) Drops 3.69% to 2024 Low - AInvest
Non-Muscle Invasive Bladder Cancer Market Set to Grow Substantially Through 2034, DelveInsight Projects | CG Oncology, Pfizer, UroGen Pharma, Janssen Research & Development, LLC, Protara Therapeutics - The Globe and Mail
Why EchoStar Stock Is Soaring Higher Today - The Globe and Mail
Two Sigma Investments LP Cuts Stock Holdings in Protara Therapeutics, Inc. (NASDAQ:TARA) - Defense World
Protara Therapeutics: Marching On To A Hopefully Eventful Back Half Of 2025 (NASDAQ:TARA) - Seeking Alpha
SoundHound AI (SOUN): This High-Potential Growth Stock Could Be Your Smartest Bet under $10 - The Globe and Mail
Where Will Uber Stock Be in 5 Years? - The Globe and Mail
Company News for Jun 13, 2025 - The Globe and Mail
Protara Therapeutics Holds Annual Stockholders Meeting - TipRanks
These 3 ‘Bro Billionaire’ Stocks Are Wildly Outperforming in Trump’s Market - The Globe and Mail
Kantar appoints Jeff Greenspoon as CEO, Americas - The Globe and Mail
Cantor Fitzgerald Forecasts TARA FY2026 Earnings - Defense World
Squarepoint Ops LLC Makes New $110,000 Investment in Protara Therapeutics, Inc. (NASDAQ:TARA) - Defense World
Steven Hudson buying at ECN Capital (ECN) - The Globe and Mail
Protara Therapeutics, Inc. (NASDAQ:TARA) Position Increased by Bank of America Corp DE - Defense World
Protara Therapeutics, Inc. (NASDAQ:TARA) Given Average Recommendation of “Buy” by Analysts - Defense World
Why Shares of Tesla Are Sinking Today - The Globe and Mail
Is Costco a Buy Now? - The Globe and Mail
Millennium Management LLC Purchases 357,051 Shares of Protara Therapeutics, Inc. (NASDAQ:TARA) - Defense World
Protara Therapeutics names new Chief Commercial Officer By Investing.com - Investing.com South Africa
Protara Therapeutics (TARA) Appoints New Chief Commercial Officer | TARA Stock News - GuruFocus
Protara Therapeutics names new Chief Commercial Officer - Investing.com
Protara Therapeutics Names William Conkling as Chief Commercial Officer - MarketScreener
Protara Therapeutics Announces Appointment Of William Conkling As Chief Commercial Officer - marketscreener.com
Protara Therapeutics Announces Appointment of William Conkling a - GuruFocus
Protara Therapeutics Announces Appointment of William Conkling as Chief Commercial Officer - GlobeNewswire
Cancer Drug Veteran Behind Trodelvy Launch Joins Protara as Commercial Chief to Lead Market Strategy - Stock Titan
The Next Stock I'm Buying? - The Globe and Mail
Transcript : Protara Therapeutics, Inc. Presents at TD Cowen's 6th Annual Oncology Innovation Summit, May-27-2025 01 - marketscreener.com
Jones Trading Initiates Coverage of Protara Therapeutics (TARA) with Buy Recommendation - Nasdaq
Protara Therapeutics (TARA) Initiates Coverage with a Buy Rating - GuruFocus
Protara Therapeutics (TARA) Initiates Coverage with a Buy Rating | TARA Stock News - GuruFocus
Protara Therapeutics (TARA) Receives Buy Rating with $21 Price T - GuruFocus
Jones Initiates Protara Therapeutics at Buy With $21 Price Target - marketscreener.com
Richard Levy Spends US$64k On Protara Therapeutics Stock - Yahoo Finance
BNP Paribas Financial Markets Purchases Shares of 151,906 Protara Therapeutics, Inc. (NASDAQ:TARA) - Defense World
Dimensional Fund Advisors LP Makes New $111,000 Investment in Protara Therapeutics, Inc. (NASDAQ:TARA) - Defense World
Richard Levy Bought 65% More Shares In Protara Therapeutics - simplywall.st
Insider Buying: Richard Levy Acquires 20,000 Shares of Protara T - GuruFocus
With 73% ownership, Protara Therapeutics, Inc. (NASDAQ:TARA) boasts of strong institutional backing - Yahoo Finance
Protara Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewswire
Protara Therapeutics Inc (TARA) 財務データ
収益
当期純利益
現金流量
EPS
3.40%
2.49%
大文字化:
|
ボリューム (24 時間):